The protein kinase C agonist PEP005 increases NF-κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

British Journal of Haematology

Volumn 145, Issue 6, 2009, Pages 761-774

  Olsnes, Astrid Marta ^a,b   Ersvær, Elisabeth ^b   Ryningen, Anita ^b   Paulsen, Kristin ^b   Hampson, Peter ^c   Lord, Janet M ^c   Gjertsen, Bjørn Tore ^b   Kristoffersen, Einar Klæboe ^d   Bruserud, Øystein ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myeloid leukaemia; Chemokines; NF B; PEP005; Protein kinase C

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BORTEZOMIB; CARBON TETRACHLORIDE; CHEMOKINE; CXCL1 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INGENOL 3 ANGELATE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEP 005; PROTEIN KINASE C ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CHEMOKINES; DITERPENES; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NF-KAPPA B; PROTEIN KINASE C; RNA INTERFERENCE; RNA, SMALL INTERFERING; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 66949164357     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07691.x     Document Type: Article

References (50)

1. Abrahamsen, J.F., Bakken, A.M. Bruserud, O. (2002) Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells. Transfusion, 42, 1573 1580.
2. Aggarwal, B.B. (2000) Apoptosis and nuclear factor-kappa B: a tale of association and dissociation. Biochemical Pharmacology, 60, 1033 1039.
3. Akella, R., Moon, T.M. Goldsmith, E.J. (2008) Unique MAP kinase binding sites. Biochimica et Biophysica Acta, 1784, 48 55.
4. Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. Saltiel, A.R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. The Journal of Biological Chemistry, 270, 27489 27494.
5. Bruserud, O. (1992) Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells. Acta Oncologica, 31, 53 58.
6. Bruserud, O. (1999) Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia, 13, 1175 1187. (Pubitemid 29396577)
7. Bruserud, O., Hovland, R., Wergeland, L., Huang, T.S. Gjertsen, B.T. (2003) Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica, 88, 416 428. (Pubitemid 36547128)
8. Bruserud, O., Ryningen, A., Wergeland, L., Glenjen, N.I. Gjertsen, B.T. (2004) Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica, 89, 391 402. (Pubitemid 38798543)
9. Bruserud, O., Ryningen, A., Olsnes, A.M., Stordrange, L., Oyan, A.M., Kalland, K.H. Gjertsen, B.T. (2007) Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica, 92, 332 341. (Pubitemid 350143542)
10. Cilloni, D., Messa, F., Rosso, V., Arruga, F., Defilippi, I., Carturan, S., Catalano, R., Pautasso, M., Panuzzo, C., Nicoli, P., Messa, E., Morotti, A., Iacobucci, I., Martinelli, G., Bracco, E. Saglio, G. (2008) Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia, 22, 1234 1240.
11. Ersvaer, E., Hampson, P., Hatfield, K., Ulvestad, E., Wendelbo, O., Lord, J.M., Gjertsen, B.T. Bruserud, O. (2007) T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology, Immunotherapy, 56, 913 925. (Pubitemid 46723583)
12. Frelin, C., Imbert, V., Griessinger, E., Peyron, A.C., Rochet, N., Philip, P., Dageville, C., Sirvent, A., Hummelsberger, M., Berard, E., Dreano, M., Sirvent, N. Peyron, J.F. (2005) Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood, 105, 804 811. (Pubitemid 40070768)
13. Garcia, M.G., Alaniz, L., Lopes, E.C., Blanco, G., Hajos, S.E. Alvarez, E. (2005) Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leukemia Research, 29, 1425 1434. (Pubitemid 41562245)
14. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M. Jordan, C.T. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 98, 2301 2307.
15. Guzman, M.L., Swiderski, C.F., Howard, D.S., Grimes, B.A., Rossi, R.M., Szilvassy, S.J. Jordan, C.T. (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 16220 16225. (Pubitemid 35462776)
16. Guzman, M.L., Rossi, R.M., Karnischky, L., Li, X., Peterson, D.R., Howard, D.S. Jordan, C.T. (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 105, 4163 4169. (Pubitemid 40720758)
17. Guzman, M.L., Rossi, R.M., Neelakantan, S., Li, X., Corbett, C.A., Hassane, D.C., Becker, M.W., Bennett, J.M., Sullivan, E., Lachowicz, J.L., Vaughan, A., Sweeney, C.J., Matthews, W., Carroll, M., Liesveld, J.L., Crooks, P.A. Jordan, C.T. (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 110, 4427 4435.
18. Hampson, P., Chahal, H., Khanim, F., Hayden, R., Mulder, A., Assi, L.K., Bunce, C.M. Lord, J.M. (2005) PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood, 106, 1362 1368. (Pubitemid 41129602)
19. Hampson, P., Kavanagh, D., Smith, E., Wang, K., Lord, J.M. Ed Rainger, G. (2008) The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunology, Immunotherapy, 57, 1241 1251.
20. Hansson, A., Marin, Y.E., Suh, J., Rabson, A.B., Chen, S., Huberman, E., Chang, R.L., Conney, A.H. Zheng, X. (2005) Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor. International Journal of Oncology, 27, 941 948.
21. Hatfield, K.J., Hovland, R., Oyan, A.M., Kalland, K.H., Ryningen, A., Gjertsen, B.T. Bruserud, O. (2008) Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia, 22, 287 293.
22. Hu, X., Park-Min, K.H., Ho, H.H. Ivashkiv, L.B. (2005) IFN-gamma-primed macrophages exhibit increased CCR2-dependent migration and altered IFN-gamma responses mediated by Stat1. Journal of Immunology, 175, 3637 3647. (Pubitemid 41292023)
23. Irish, J.M., Hovland, R., Krutzik, P.O., Perez, O.D., Bruserud, O., Gjertsen, B.T. Nolan, G.P. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell, 118, 217 228. (Pubitemid 38962577)
24. Joiakim, A., Mathieu, P.A., Palermo, C., Gasiewicz, T.A. Reiners, Jr., J.J. (2003) The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metabolism and Disposition, 31, 1279 1282. (Pubitemid 37310311)
25. Kedei, N., Lundberg, D.J., Toth, A., Welburn, P., Garfield, S.H. Blumberg, P.M. (2004) Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Research, 64, 3243 3255. (Pubitemid 38581429)
26. Mayo, M.W. Baldwin, A.S. (2000) The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochimica et Biophysica Acta, 1470, M55 M62.
27. Mohle, R., Bautz, F., Rafii, S., Moore, M.A., Brugger, W. Kanz, L. (1998) The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood, 91, 4523 4530. (Pubitemid 28270300)
28. Montenegro, D.E., Franklin, T., Moscinski, L.C., Zuckerman, K.S. Hu, X.T. (2009) TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k). Cell Proliferation, 42, 1 9.
29. Moser, B., Wolf, M., Walz, A. Loetscher, P. (2004) Chemokines: multiple levels of leukocyte migration control. Trends in Immunology, 25, 75 84. (Pubitemid 38167488)
30. Nakanishi, C. Toi, M. (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nature Reviews. Cancer, 5, 297 309. (Pubitemid 40488635)
31. Nemoto, S., Xiang, J., Huang, S. Lin, A. (1998) Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. The Journal of Biological Chemistry, 273, 16415 16420. (Pubitemid 28311422)
32. Ogbourne, S.M., Suhrbier, A., Jones, B., Cozzi, S.J., Boyle, G.M., Morris, M., McAlpine, D., Johns, J., Scott, T.M., Sutherland, K.P., Gardner, J.M., Le, T.T., Lenarczyk, A., Aylward, J.H. Parsons, P.G. (2004) Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Research, 64, 2833 2839. (Pubitemid 38500622)
33. Olsnes, A.M., Motorin, D., Ryningen, A., Zaritskey, A.Y. Bruserud, O. (2006) T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunology, Immunotherapy, 55, 830 840.
34. Olsnes, A.M., Ryningen, A., Ersvær, E. Bruserud, Ø. (2008) In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. Journal of Interferon & Cytokine Research, 28, 297 310.
35. Park, C., Jin, C.Y., Kim, G.Y., Choi, I.W., Kwon, T.K., Choi, B.T., Lee, S.J., Lee, W.H. Choi, Y.H. (2008) Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. Toxicology and Applied Pharmacology, 227, 219 228.
36. Rombouts, E.J., Pavic, B., Lowenberg, B. Ploemacher, R.E. (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood, 104, 550 557. (Pubitemid 38900040)
37. Ryningen, A., Wergeland, L., Glenjen, N., Gjertsen, B.T. Bruserud, O. (2005) In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia Research, 29, 185 196. (Pubitemid 39650954)
38. Ryningen, A., Ersvaer, E., Oyan, A.M., Kalland, K.H., Vintermyr, O.K., Gjertsen, B.T. Bruserud, O. (2006) Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low bcl-2:bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research, 30, 1531 1540. (Pubitemid 44573475)
39. Ryningen, A., Stapnes, C., Paulsen, K., Lassalle, P., Gjertsen, B.T. Bruserud, O. (2008) In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs, 17, 1623 1633.
40. Saharinen, P., Ekman, N., Sarvas, K., Parker, P., Alitalo, K. Silvennoinen, O. (1997) The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. Blood, 90, 4341 4353. (Pubitemid 27508440)
41. Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C. Kern, W. (2004) Adult acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 50, 197 222. (Pubitemid 38746534)
42. Sperling, C., Schwartz, S., Buchner, T., Thiel, E. Ludwig, W.D. (1997) Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica, 82, 617 621. (Pubitemid 28023263)
43. Stapnes, C., Doskeland, A.P., Hatfield, K., Ersvaer, E., Ryningen, A., Lorens, J.B., Gjertsen, B.T. Bruserud, O. (2007) The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology, 136, 814 828. (Pubitemid 46348414)
44. Steinberg, S.F. (2004) Distinctive activation mechanisms and functions for protein kinase Cdelta. The Biochemical Journal, 384, 449 459. (Pubitemid 40018958)
45. Sunwoo, J.B., Chen, Z., Dong, G., Yeh, N., Crowl Bancroft, C., Sausville, E., Adams, J., Elliott, P. Van Waes, C. (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clinical Cancer Research, 7, 1419 1428. (Pubitemid 32708698)
46. Tan, H., Ling, H., He, J., Yi, L., Zhou, J., Lin, M. Su, Q. (2008) Inhibition of ERK and activation of p38 are involved in diallyl disulfide induced apoptosis of leukemia HL-60 cells. Archives of Pharmacal Research, 31, 786 793.
47. Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V. Baldwin, Jr., A.S. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281, 1680 1683.
48. Wergeland, L., Sjoholt, G., Haaland, I., Hovland, R., Bruserud, O. Gjertsen, B.T. (2007) Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer, 6, 33.
49. Yang, J., Amiri, K.I., Burke, J.R., Schmid, J.A. Richmond, A. (2006) BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clinical Cancer Research, 12, 950 960. (Pubitemid 43259878)
50. Yang, Y., Kitagaki, J., Wang, H., Hou, D.X. Perantoni, A.O. (2009) Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Science, 100, 24 28.